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Aims To investigate whether improved survival from non-ST-elevation myocardial infarction (NSTEMI), according to
GRACE risk score, was associated with guideline-indicated treatments and diagnostics, and persisted after hospital
discharge.
...................................................................................................................................................................................................
Methods
and results
National cohort study (n= 389 507 patients, n= 232 hospitals, MINAP registry), 2003–2013. The primary outcome
was adjusted all-cause survival estimated using flexible parametric survival modelling with time-varying covariates.
Optimal care was defined as the receipt of all eligible treatments and was inversely related to risk status (defined by
the GRACE risk score): 25.6% in low, 18.6% in intermediate, and 11.5% in high-risk NSTEMI. At 30 days, the use of
optimal care was associated with improved survival among high [adjusted hazard ratio (aHR) -0.66 95% confidence
interval (CI) 0.53–0.86, difference in absolute mortality rate (AMR) per 100 patients (AMR/100–0.19 95% CI -0.29 to
-0.08)], and intermediate (aHR = 0.74, 95% CI 0.62–0.92; AMR/100 = -0.15, 95% CI -0.23 to -0.08) risk NSTEMI. At
the end of follow-up (8.4 years, median 2.3 years), the significant association between the use of all eligible guideline-
indicated treatments and improved survival remained only for high-risk NSTEMI (aHR = 0.66, 95% CI 0.50–0.96; AMR/
100 = -0.03, 95% CI -0.06 to -0.01). For low-risk NSTEMI, there was no association between the use of optimal care
and improved survival at 30 days (aHR = 0.92, 95% CI 0.69–1.38) and at 8.4 years (aHR = 0.71, 95% CI 0.39–3.74).
...................................................................................................................................................................................................
Conclusion Optimal use of guideline-indicated care for NSTEMI was associated with greater survival gains with increasing
GRACE risk, but its use decreased with increasing GRACE risk.
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Introduction
For patients with non-ST-elevation myocardial infarction (NSTEMI),
evidence from international studies suggests that guideline-indicated
care treatment and diagnostics are associated with improved clinical
outcomes.1–4 Evidence from randomized controlled trials, suggest
that the absolute effect is greater for NSTEMI at high ischaemic risk
where there is reduced mortality, and lower rates of unscheduled
revascularization, stroke, and hospitalization for heart failure.5–8 It is
unknown, however, if beyond the setting of trials the effects of such
interventions for NSTEMI (including pharmacotherapies as well as an
invasive coronary strategy) are evident and, if so, whether such
effects persist after discharge from hospital.
The Myocardial Ischaemia National Audit Project (MINAP) repre-
sents all acute hospitals in the single healthcare system of England and
Wales and prospectively collects information about treatments pro-
vided, case mix and mortality of patients hospitalized with acute cor-
onary syndrome over 15 years.9,10 Thus, MINAP is an optimal
research conduit for understanding the impact of evidence-based
NSTEMI care on clinical outcomes. We accessed anonymized patient
data from MINAP to investigate whether improved survival associ-
ated with the use of NSTEMI guideline-indicated treatments was evi-
dent across the spectrum of NSTEMI risk, and whether mortality
benefits were maintained over the long-term following discharge
from hospital.
Methods
Data and subjects
The study was conducted using the MINAP. Data were entered electron-
ically at each hospital where they were encrypted prior to secure transfer
to a central database, anonymized and then distributed upon application
for research. Each year MINAP data are validated at participating
hospitals.9
The study population included all patients (1 January 2003 to 30 June
2013) with a discharge diagnosis of NSTEMI. This diagnosis was deter-
mined by the treating team and based upon clinical presentation and
investigations, including biomarkers, in keeping with the universal defin-
ition of myocardial infarction.11 Patients who died in hospital (n= 31 321)
and for whom, there were no survival data (n= 21 567) were excluded
from the cohort in keeping with previous work (Figure 1).3
Baseline clinical risk was determined according to the adjusted mini-
GRACE risk score, which has been validated using MINAP data and
endorsed by the National Institute for Health and Care Excellence
(NICE).12,13 The variables included age, cardiac arrest, electrocardio-
graphic ST-segment deviation, elevated cardiac enzymes, systolic blood
pressure and heart rate at the time of hospitalization, use of a loop diuret-
ic (substituted for Killip Class), and creatinine. In line with the American
Heart Association/American College of Cardiology and European
Society of Cardiology NSTEACS guidelines,14,15 we categorized patients
according to their risk of in-hospital mortality using the calculated
GRACE risk score as low (<109; predicted mortality <1.0%), intermedi-
ate (>_109 to <_140; predicted mortality >_1.0% to <_3.0%), and high
(>140; predicted mortality >3.0%).
Receipt of guideline indicated care was measured according to a com-
posite optimal care variable. This comprised 13 care interventions, previ-
ously mapped to MINAP data by the authors,2 which were identified
following review of international guidelines.16–20 The 13 interventions
included receipt, if eligible, of an electrocardiogram pre- or in-hospital,
pre-hospital receipt of aspirin, echocardiography, an aldosterone antag-
onist during admission, coronary angiography, aspirin on discharge, P2Y12
inhibition on discharge, ACE inhibitors (ACEi)/angiotensin receptor
blockers (ARBs) on discharge, b-blocker on discharge, HMG Co-A re-
ductase inhibitor (statin) on discharge, referral for cardiac rehabilitation,
smoking cessation advice, and dietary advice (see Supplementary material
online, Section S1).2,3 Patients were classified as ineligible if a treatment
was listed as contraindicated, not indicated, not applicable, if the patient
declined treatment as recorded in MINAP or if the patient was hospital-
ized prior to the publication year of treatment recommendation in the
guidelines. If patients were deemed eligible, but there was no data regard-
ing receipt, they were assumed to have not received that intervention.
Optimal care was defined at the individual patient level, if they received all
of the care opportunities for which an individual patient was eligible; thus,
patients missing one or more eligible care opportunities were assigned to
the suboptimal care group. Patients who were listed as having a contra-
indication for one care intervention were not eligible for that care inter-
vention and only the care interventions for which a patient was eligible
for were considered in the calculation of the optimal care variable.
We also studied the impact of optimal care compared with suboptimal
care for components of the care pathway separately, including pharmaco-
logical therapies [pre-hospital receipt of aspirin, aldosterone antagonist
during admission, aspirin on discharge, P2Y12 inhibition on discharge,
ACEi/ARBs on discharge, b-blocker on discharge and HMG Co-A reduc-
tase inhibitor (statin) on discharge), investigative and invasive coronary
strategies (receipt of a pre- or in-hospital electrocardiogram, echocardi-
ography and coronary angiography), and lifestyle care opportunities (re-
ferral for cardiac rehabilitation, receipt of smoking cessation advice and
receipt of dietary advice)].
The primary outcome measure was all-cause mortality after discharge
from hospital up to the maximum follow-up time of 8.4 years [median
2.3, interquartile range (IQR) 1.1–3.9 years], which represented over
1 079 044 person years. Mortality data were obtained via linkage to the
United Kingdom national death records held by the Office for National
Statistics.
Statistical analysis
Baseline characteristics were described using numbers and percentages
for categorical data and means and standard deviations or medians and
IQRs for normal and non-normally distributed continuous variables.
Differences in patient characteristics according to patient demographic
and baseline clinical data were compared across GRACE risk score cate-
gories using v2, t-tests, and Wilcoxon rank-sum tests as appropriate for
the data type and distribution.
Flexible parametric survival modelling21 was used to assess the associ-
ation of optimal care with long-term survival according to GRACE risk
score category. To model the change in hazard ratio (HR) over continu-
ous follow-up time, optimal care, and GRACE risk score categories were
included in the model as time-varying covariates. We selected flexible
parametric survival modelling to overcome violation of the proportional
hazards assumption and to estimate the baseline hazard function using
restricted cubic splines (see Supplementary material online, Section S2,
Table S2 for model selection choice). The model was adjusted for patient
demographics (sex, Index of Multiple Deprivation), medical history [dia-
betes, smoking status, family history of coronary heart disease, hyperten-
sion, previous myocardial infarction, previous angina, peripheral vascular
disease, cerebrovascular disease, chronic obstructive pulmonary disease
or asthma, chronic renal failure (defined as creatinine chronically
>200mmol/L (>2.26 mg/dL)), congestive cardiac failure, previous percu-
taneous coronary intervention, coronary artery bypass graft surgery, and
total cholesterol]. Survival differences were quantified as HRs and
2 M. Hall et al.
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differences in absolute mortality rates (AMR) per 100 patients, with an
AMR of zero indicating no differences in mortality rates between the op-
timally treated patients (received all care interventions they were eligible
for) vs. those sub-optimally treated. However, an AMR less than zero
indicates lower mortality rates in the optimally managed patients com-
pared with the sub-optimally managed.
Multiple imputation by chained equations was used to produce 10
imputed datasets to minimize potential bias caused by missing data. Of
the 34 MINAP variables considered in the study (Table 1), the majority
had less than 10% missing data (n= 26). Overall, we had complete data
across all variables included in the flexible parametric modelling for
184 390 of patients. Multiple imputation by chained equations allowed
the inclusion all 389 057 patients in the main study analyses and, as such,
prevented loss of information whilst mitigating potential bias from missing
data. Pooled model estimates and accompanying 95% confidence inter-
vals (CIs) were generated according to Rubin’s rules (see Supplementary
material online, Section S3, Table S3).22 All imputed data were compared
with complete case analyses according to imputation good practice
guidelines (see Supplementary material online, Table S4).23 All tests were
two-sided, and statistical significance was considered as P< 0.05.
Statistical analyses were performed in Stata MP64 version 14 (http://
www.stata.com/) and R version 3.1.2 (https://cran.r-project.org/).
Ethical considerations
MINAP is managed by the National Institute for Cardiovascular
Outcomes Research (NICOR) (ref. NIGB: ECC 1-06 (d)/2011). NICOR
has support under section 251 of the NHS Act 2006 for the conduction
of medical research utilizing patient information without formal consent.
Formal ethical approval was not required for this study under NHS re-
search governance arrangements for use of non-identifiable patient data.
The research complies with the Declaration of Helsinki.
Results
There were 389 057 patients included in the study with median age
of 73 years (IQR 62–81 years) and 143 388 (36.9%) were female
(Figure 1). There were more low risk [73 351 (39.7%)] than inter-
mediate risk [59 201 (32.1%)] and high risk [52 005 (28.2%)] patients
with NSTEMI (Table 1). High-risk NSTEMI were older than inter-
mediate and low-risk NSTEMI [84 (79–88) vs. 76 (70–81) vs. 59 (52–
66) years, respectively] and more likely to be female (47.9% vs. 40.2%
vs. 26.6%). In general, levels of co-morbidity increased with increasing
GRACE risk score category (Table 1). However, smoking decreased
with increasing GRACE risk score category, and a family history of is-
chaemic heart disease was more frequent in the lower GRACE risk
score group. Summary data for patients in whom the GRACE risk
score was missing, prior to multiple imputation, is provided in
Supplementary material online, Section S4, Table S5.
In total, 44 530 (11.5%) patients received optimal care, with the
median proportion of eligible care received being 70.0% (IQR 55.6–
85.7%). Care interventions most frequently not provided were re-
ceipt of aldosterone antagonists during admission [9426 (82.5%)],
provision of smoking cessation advice [133 726 (80.6)], provision of
dietary advice [254 869 (68.1)], and receipt of echocardiogram
[181 831 (46.7)]. Both receipt of optimal care and the proportion of
care received decreased with increasing GRACE risk score category
[optimal care 18 785 (25.6%) and proportion of care 83.3% (IQR
66.7–100) for low-risk NSTEMI vs. 5958 (11.5%) and 72.7% (IQR
60.0–87.5) for high-risk NSTEMI; P< 0.001] (Table 1, Supplementary
material online, Figure S1). Receipt of care did not vary significantly by
GRACE risk score for electrocardiogram and aspirin on discharge,
but increased for in-hospital aldosterone receptor blocker (13.4%,
19.4%, and 20.3% for low-, intermediate-, and high-risk patients, re-
spectively). Whilst receipt of care decreased with increasing GRACE
risk score for all other care opportunities, the greatest decreases
were observed for coronary angiography (85.4%, 65.7%, and 38%),
pre-hospital aspirin (71.1%, 60.0%, and 47.1%), and smoking cessation
advice (48.7%, 29.5%, and 18.4%) for low-, intermediate-, and high-
risk patients, respectively. Patients with missing GRACE risk score
data had similar characteristics to those with complete GRACE risk
score data, except for optimal care (8795, 4.3%) and the proportion
of care received (63%, IQR 50–75%), which were lower (see
Supplementary material online, Section S4, Table S5).
Mortality, guideline-indicated treat-
ments, and ischaemic risk
There were 113 856 (29.2%) deaths corresponding to 10.5 deaths
per 100 person years. A pattern of greater early hazard for death was
evident across the spectrum of NSTEMI risk, and accentuated among
high-risk NSTEMI (Figure 2). Across all GRACE risk score groups for
landmark time periods 0–1 years, 1–2 years, and 2–3 years, but not
3–8 years, unadjusted mortality rates were significantly higher for
patients who did not receive optimal care (Figure 3). After adjust-
ment, there remained a benefit in receiving optimal care regardless of
estimated ischaemic risk. [Adjusted hazard ratio (aHR) = 0.62 (95%
CI 0.56–0.68) difference in absolute mortality rate per 100 patients
(AMR/100) -0.01 (95% CI -0.01 to 0.00) Table 2].
At 30 days, the use of all eligible guideline-indicated treatments
was associated with improved survival among high risk NSTEMI
[aHR = 0.66 (95% CI 0.53–0.86) AMR/100 -0.19 (95% CI -0.29 to
-0.08)], and intermediate risk NSTEMI [aHR = 0.74 (95% CI 0.62–
0.92); AMR/100 -0.15 (95% CI -0.23 to -0.08) Table 3]. At the end of
Figure 1 Consort diagram of exclusions of the Myocardial
Ischaemia National Audit Project (MINAP) dataset.
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follow-up (8.4 years), the significant association between the use of
all eligible guideline-indicated treatments and improved survival
remained for high-risk NSTEMI (aHR = 0.66, 95% CI 0.50–0.96;
AMR/100 = -0.03, 95% CI -0.06 to -0.01), but not for intermediate-
risk NSTEMI (aHR = 1.04, 95% CI 0.74–1.71; AMR/100 = 0.002, 95%
CI -0.02 to 0.03). For the low-risk NSTEMI, there was no association
between use of all compared with the use of some eligible guideline-
indicated treatments and improved survival at 30-days (aHR = 0.92,
95% CI 0.69–1.38) and at 8.4 years (aHR = 0.71, 95% CI 0.39–3.74). A
sensitivity analysis, which included in-hospital deaths made minimal
difference to the effect directions and magnitudes (see
Supplementary material online, Section S5, Table S6).
Of the three subgroups of guideline-indicated care treatments and
diagnostics, investigative and invasive coronary strategy was associ-
ated with the most comprehensive impact on survival—including
beneficial effects among low-, intermediate-, and high-risk NSTEMI as
well as effects that persisted the longest for the high-risk group
(Figure 2, Supplementary material online, Tables S7a–S7c). For inter-
mediate-risk NSTEMI, investigative and invasive coronary strategies
were associated with a 28% relative survival improvement up to
3 years (aHR = 0.72, 95% CI 0.57–0.98; AMR/100 = -0.03, 95% CI
-0.06 to -0.01), and for high-risk NSTEMI a 19% survival improvement
at 8 years (aHR = 0.81, 95% CI 0.69–0.97; AMR/100 = -0.02, 95% CI
-0.03 to -0.01). Pharmacological therapies were associated with a
46% survival improvement at 6 years (aHR = 0.54, 95% CI 0.37–0.97;
AMR/100 = -0.02, 95% CI -0.04 to -0.01) for low-risk NSTEMI, and a
25% survival improvement at 5 years (aHR = 0.75, 95% CI 0.61–0.99;
AMR/100 = -0.02, 95% CI -0.04 to 0.00) for intermediate-risk
NSTEMI, with no persisting effect for high-risk NSTEMI. Lifestyle care
opportunities were associated with a 25% survival improvement at
8 years (aHR = 0.75, 95% CI 0.63–0.92; AMR/100 = -0.02, 95% CI
-0.04 to -0.01) for high-risk NSTEMI, but no persisting effect for low-
or intermediate-risk NSTEMI.
Discussion
In this prospective observational cohort study of 389 057 patients
with NSTEMI using data for all acute hospitals in a single health care
system, optimal use of guideline-indicated care for NSTEMI was asso-
ciated with greater survival gains with increasing GRACE risk, but its
use decreased with increasing GRACE risk. Of note, is that the mor-
tality benefit associated with optimal care found in high-risk NSTEMI
persisted for over eight years from the time of discharge from hos-
pital. Whilst there was a preponderance of low-risk NSTEMI patients
who had high rates of survival, these patients proportionally received
more evidence-based care compared with intermediate and high-risk
NSTEMI. Moreover, a pattern of early death was evident across the
NSTEMI risk spectrum, which was accentuated for those with the
highest GRACE risk scores. Taken together, these findings suggest
that providing all eligible care opportunities to NSTEMI patients has
the potential to improve survival, and that those at highest risk will
derive greater and more sustained benefit.
To our knowledge, this is the first study to investigate how long
the impact of the pathway of guideline-indicated care according to
baseline ischaemic risk among eligible patients with NSTEMI persists.
Previous work has demonstrated that guideline-directed therapy
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results in improved outcomes at 30 days and 3 years, yet is limited be-
cause it focuses on the performance of finite quality indicators or
interventions rather than cumulative care.3,24–26 This is important be-
cause the treatment of NSTEMI follows a journey of care and defined
by evidence from randomized controlled trials and observational
studies.14,15 Whilst earlier studies have demonstrated excess mortal-
ity associated with the non-receipt of guideline indicated interven-
tions along the pathway of care, the potential persistence of effect
sizes was not studied.2
Low-risk NSTEMI who received all eligible care interventions did
not have a significant survival advantage compared with their coun-
terparts who received some or none of the eligible care interven-
tions. Whilst this seems counterintuitive, especially when
randomized data have demonstrated clinical benefit from evidence—
based treatments for NSTEMI,27 there are a number of possible
explanations. First, the low GRACE risk score comparator group had
high rates of receipt of many care interventions; therefore, although
care was not optimal for 54 566 patients in this group, it was still high
overall (median receipt of care 83.3%), and indeed, those with a low
GRACE risk score comprised the greatest proportion of patients
with the highest receipt of care. Second, the low rates of death in the
low GRACE risk score group created a ‘floor effect’ whereby the dis-
crimination of differences between optimal and suboptimal care was
not possible.
We found that an invasive coronary strategy was associated with
the most comprehensive and persistent impact on survival. Such an
approach to the treatment of NSTEMI improved survival for inter-
mediate and high-risk patients—with effects lasting for many years
after hospital discharge following treatment. We noted that the
beneficial survival effect associated with pharmacotherapies was
Figure 2 Adjusted* time-varying mortality rates by receipt of optimal care and clinical risk obtained from a flexible parametric model (odds scale,
five degrees of freedom) with time varying covariates by GRACE risk score category for optimal care vs. suboptimal care across the full care pathway
(A) and by the following subgroups of the care pathway: pharmacological therapies (B)†, investigative and invasive coronary strategies (C)‡, and life-
style (D)§,.ˆ P= 0.004 for interaction. GRACE, Global registry of Acute Coronary Events, categorized into low (<109), intermediate (109 to <_140),
and high (>140) risk. *Model adjusted for demographic characteristics including sex, year, deprivation, previous acute myocardial infarction, previous
angina, previous PCI, previous CABG, hypertension, peripheral vascular disease, chronic renal failure, chronic heart failure, cerebrovascular disease,
diabetes mellitus, smoking status, and elevated cholesterol. †Including pre-hospital receipt of aspirin, aldosterone antagonist during admission, aspirin
on discharge, P2Y12 inhibition on discharge, ACE inhibitors (ACEi)/angiotensin receptor blockers (ARBs) on discharge, b-blocker on discharge, and
HMG Co-A reductase inhibitor (statin) on discharge. ‡Including receipt of a pre- or in-hospital electrocardiogram, echocardiography and coronary
angiography. §Including referral for cardiac rehabilitation, smoking cessation advice and dietary advice.
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..restricted to low- and intermediate-risk NSTEMI for approximately
6 years after hospital discharge, whereas lifestyle modifications were
associated with improved survival for up to 8 years among high-risk
NSTEMI. We speculate that this differential association with survival
may be because the effect of other care interventions such as an inva-
sive strategy is greater than that of pharmacotherapies.3 Indeed, the
advantages of an invasive strategy on early and mid-term clinical out-
comes have been demonstrated in randomized studies,7,24 yet until
now the evidence for its impact on longer-term outcomes has been
limited.28 Our ‘real world’ national study supports these mid-term
outcomes data, but also suggests that the impact of coronary angiog-
raphy and revascularization for NSTEMI extends to at least 8 years.
The utilization of risk scores is recommended by international
guidelines.13–15 In part, this is because physicians underestimate fu-
ture ischaemic risk for NSTEMI which in turn contributes to subopti-
mal use of treatments.30,31 Our research supports the use of
accurate risk estimation for NSTEMI, and is in keeping with evidence
indicating that the GRACE risk score may be used to predict long-
term outcomes.31–34 Using a validated risk stratification tool such as
the GRACE risk score, may enable earlier mobilization of care
interventions, and therefore, reduce fatal and non-fatal cardiovascular
events.35,36
Moreover, the international burden of NSTEMI burden is high and
is set to increase, with associated high mortality rates in the medium
to longer-term.29,30 It is evident that the opportunities to improve
care, and therefore realize reductions in cardiovascular endpoints fol-
lowing acute myocardial infarction, are unmet.1,2,25,36–38 Given that
all of the interventions selected in this study were based on Class 1
recommendations that have been demonstrated to improve out-
comes for NSTEMI, a decline in mortality rates should follow an in-
crease in adherence to guideline-indicated care, with greater and
persisting benefits among the higher risk.
To our knowledge, MINAP is the largest whole-country, single
health system, prospective observational cohort of the quality of care
and clinical outcomes across the spectrum of acute coronary syn-
dromes. It is designed to be representative of the management of
acute coronary syndrome in a clinical setting and has standardized
criteria for defining case mix and treatments. Nevertheless, there
were limitations to our study. First, the study was reliant on accurate
recording of data, receipt of dietary and smoking advice was low this
Figure 3 Unadjusted landmark Kaplan–Meier survival curves and crude mortality rates by GRACE risk score category and receipt of optimal care
vs. suboptimal care. This figure demonstrates the benchmarked crude mortality rates for the following time periods; 0–1 year, 1–2 years, 2–3 years,
3–8 years, across GRACE risk category by the receipt of optimal care. The percentages represent the crude mortality rates for each time period
with the 95% confidence interval for each of the respective GRACE risk score categories. Population at risk at baseline; low GRACE risk category:
73 351, intermediate GRACE risk category: 59 201, high GRACE risk category: 52 005. Population at risk 3–8 years; low GRACE risk category:
70 069 intermediate GRACE risk category: 47 120, high GRACE risk category: 28 698.
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.. may be because the receipt of verbal advice is not well recorded.
Second, MINAP does not collect all diagnosed cases of NSTEMI with-
in England and Wales, whereby estimates of cases of acute myocar-
dial infarction may be reduced by half compared with a multi-
electronic health records approach.39 Third, missing data could have
biased the estimates. However, an imputation strategy to minimize
bias was implemented.37,40 Fourth, it is probable that other factors
beyond the hospital stay (such as drug adherence and primary care
visits) may also have influenced survival. Fifth, all-cause mortality was
studied because cause specific mortality data were not available. This
is a limitation because non-cardiovascular deaths may not be attribut-
able to NSTEMI care.41 Sixth, in-hospital deaths were excluded,
which could have resulted in survivorship bias—even so, a sensitivity
analysis revealed that exclusion of these cases did not affect the con-
clusions drawn. Seventh is that the non-receipt of guideline care
treatment and diagnostics may be a marker of higher NSTEMI risk.
Indeed, we found that higher attainment of care occurred for lower
risk NSTEMI. Finally, this observational study cannot demonstrate
causation.
Conclusion
For nearly 400 000 NSTEMI hospital survivors in England and Wales,
guideline-indicated treatment was less frequent among the high-risk
NSTEMI, but when provided was significantly associated with
improved survival which persisted over the longer-term. There was
benefit seen in those at lower risk, though this was not significant
.................................................................
.................................................................................................
Table 2 Time-varying adjusted hazard ratios and ab-
solute difference in mortality rate per 100 for patients
receiving optimal care compared with suboptimal care
after multiple imputation for missing data
Optimal care vs. suboptimal care
aHRa Difference in AMR/100
HR over total
follow-up time
0.62 (0.56–0.68) -0.01 (-0.01 to 0.00)
30 days 0.72 (0.63–0.84) -0.02 (-0.03 to -0.01)
1 0.57 (0.47–0.73) -0.01 (-0.02 to -0.01)
2 0.56 (0.44–0.77) -0.01 (-0.02 to -0.01)
3 0.56 (0.43–0.80) -0.01 (-0.01 to 0.00)
4 0.56 (0.42–0.82) -0.01 (-0.01 to 0.00)
5 0.56 (0.42–0.84) -0.01 (-0.01 to 0.00)
6 0.56 (0.42–0.86) -0.01 (-0.01 to 0.00)
7 0.56 (0.42–0.87) -0.01 (-0.01 to 0.00)
8 0.57 (0.42–0.89) -0.01 (-0.01 to 0.00)
aHR, adjusted hazard ratio; AMR, absolute mortality rate.
aaHR—adjusted hazard ratio obtained from flexible parametric survival modelling
on the odds scale with five degrees of freedom and time-varying covariates for
optimal care and GRACE risk, adjusted for: patient demographics (sex, year, and
Index of Multiple Deprivation) and medical history (history of diabetes, smoking
status, family history of coronary heart disease, hypertension, previous myocar-
dial infarction, previous angina, peripheral vascular disease, cerebrovascular dis-
ease, chronic obstructive pulmonary disease or asthma, chronic renal failure,
congestive cardiac failure, previous percutaneous coronary intervention, previous
coronary artery bypass graft surgery, and total cholesterol).
......................................................... ......................................................... .........................................................
......................................................... ......................................................... .........................................................
....................................................................................................................................................................................................................
Table 3 Time-varying adjusted hazard ratios and absolute difference in mortality rate per 100 for patients receiving
optimal care compared with suboptimal care according to low, intermediate and high GRACE risk score category after
multiple imputation for missing data*
Optimal care vs. suboptimal care Optimal care vs. suboptimal care Optimal care vs. suboptimal care
Low GRACE risk Intermediate GRACE risk High GRACE risk
aHRa Difference in
AMR/100
aHRa Difference in
AMR/100
aHRa Difference in
AMR/100
HR over total
follow-up time
0.76 (0.60–0.96) -0.01 (-0.02 to -0.002) 0.66 (0.56–0.77) -0.03 (-0.04 to -0.02) 0.55 (0.48–0.63) -0.07 (-0.09 to -0.05)
Time varying HRs
30 days 0.92 (0.69–1.38) -0.01 (-0.06 to 0.03) 0.74 (0.62–0.92) -0.15 (-0.23 to -0.08) 0.66 (0.53–0.86) -0.19 (-0.29 to -0.08)
1 0.71 (0.47–1.49) -0.02 (-0.04 to 0.01) 0.85 (0.64–1.25) -0.03 (-0.08 to 0.02) 0.53 (0.42–0.74) -0.18 (-0.25 to -0.12)
2 0.71 (0.43–1.93) -0.01 (-0.04 to 0.01) 0.92 (0.66–1.47) -0.01 (-0.06 to 0.04) 0.56 (0.42–0.82) -0.12 (-0.17 to -0.07)
3 0.70 (0.42–2.31) -0.01 (-0.03 to 0.01) 0.96 (0.68–1.58) -0.0050 (-0.05 to 0.04) 0.58 (0.44–0.87) -0.09 (-0.13 to -0.05)
4 0.70 (0.41–2.66) -0.01 (-0.03 to 0.01) 0.98 (0.70–1.65) -0.0017 (-0.04 to 0.04) 0.60 (0.45–0.90) -0.07 (-0.1 to -0.03)
5 0.71 (0.40–2.97) -0.01 (-0.03 to 0.01) 1.00 (0.71–1.68) 0.0001 (-0.03 to 0.03) 0.62 (0.46–0.92) -0.06 (-0.09 to -0.02)
6 0.71 (0.40–3.25) -0.01 (-0.03 to 0.01) 1.02 (0.72–1.70) 0.0012 (-0.03 to 0.03) 0.63 (0.48–0.94) -0.05 (-0.07 to -0.2)
7 0.71 (0.39–3.51) -0.01 (-0.02 to 0.01) 1.03 (0.74–1.71) 0.0019 (-0.03 to 0.03) 0.64 (0.49–0.95) -0.04 (-0.06 to -0.02)
8 0.71 (0.39–3.74) -0.01 (-0.02 to 0.01) 1.04 (0.74–1.71) 0.0023 (-0.02 to 0.03) 0.66 (0.50–0.96) -0.03 (-0.06 to -0.01)
aHR, adjusted hazard ratio; AMR, absolute mortality rate; GRACE, Global registry of Acute Coronary Events, categorized into low (<109), intermediate (109 to <_140), and
high (>140) risk.
aaHR—adjusted hazard ratio obtained from flexible parametric survival modelling on the odds scale with five degrees of freedom and time-varying covariates for optimal care
and GRACE risk, adjusted for: patient demographics (sex, year, and Index of Multiple Deprivation) and medical history (history of diabetes, smoking status, family history of cor-
onary heart disease, hypertension, previous myocardial infarction, previous angina, peripheral vascular disease, cerebrovascular disease, chronic obstructive pulmonary disease
or asthma, chronic renal failure, congestive cardiac failure, previous percutaneous coronary intervention, previous coronary artery bypass graft surgery, and total cholesterol).
*P< 0.001 for interaction.
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.
over the whole study period. The provision of ‘up to standard’
guideline-indicated care for high-risk NSTEMI has the potential to im-
prove their longer-term survival.
Supplementary material
Supplementary material is available at European Heart Journal online.
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